Paper Details

  1. Home
  2. Paper Details

The use of sacubitril/valsartan in anthracycline-induced cardiomyopathy: A mini case series.

Author: AnwarMaria, SheppardChristina E

Case ReportsIn the medical field, a report that describes in detail a unique case, an unusual medical condition, or the effect of a treatment. Provides new insights and possibilities for treatment through individual patient cases.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

Sacubitril/valsartan has been shown to be beneficial in heart failure patients but has not been evaluated in patients with chemotherapy-induced cardiomyopathy. This article suggests that the drug combination might be a viable option for managing cancer patients who develop heart failure based on current guidelines.
Paper Details　
Original Abstract of the Article :
Sacubitril/valsartan has been shown to significantly reduce cardiovascular mortality and hospitalizations due to heart failure in adult patients with reduced ejection fraction when compared to enalapril. To the best of our knowledge, the combination of sacubitril (neprilysin inhibitor) and valsartan...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1177/1078155218783238

データ提供：米国国立医学図書館（NLM）

Sacubitril/Valsartan: A New Oasis in the Desert of Anthracycline-Induced Cardiomyopathy?

The field of [cardiovascular medicine] is constantly seeking better treatments for [heart failure] and its various causes. This research explores the potential benefits of [sacubitril/valsartan] in treating [anthracycline-induced cardiomyopathy], a serious side effect of certain cancer treatments.

The authors present a mini case series exploring the use of [sacubitril/valsartan] in patients with [anthracycline-induced cardiomyopathy]. This research is particularly valuable because these patients were excluded from the major clinical trial, PARADIGM-HF. The authors' findings highlight the potential benefits of [sacubitril/valsartan] for this specific patient population and provide further evidence for its use in [heart failure] management.

A New Oasis for Cardiomyopathy?

This research offers a promising glimpse into a potential new treatment strategy for [anthracycline-induced cardiomyopathy]. The authors' findings suggest that [sacubitril/valsartan] may be a valuable addition to the treatment armamentarium for patients experiencing [heart failure] following cancer therapy. Further research is needed to fully understand its effectiveness and safety in this specific population.

Navigating the Sands of Cardiomyopathy: What Does This Mean for You?

If you are undergoing cancer treatment with [anthracyclines], it is important to be aware of the potential risk of [cardiomyopathy]. This research offers hope for patients with [anthracycline-induced cardiomyopathy], suggesting that [sacubitril/valsartan] may be a viable treatment option to help manage the challenges associated with this condition.

Dr. Camel's Conclusion

This research represents a step forward in the quest for more effective treatments for [heart failure]. The potential of [sacubitril/valsartan] in [anthracycline-induced cardiomyopathy] offers a glimmer of hope in the often-challenging landscape of cardiovascular disease. Further research is needed to fully explore the potential benefits and risks of this promising new treatment.

Date :
  1. Date Completed 2019-07-09
  2. Date Revised 2021-12-04
Further Info :

Pubmed ID

29945530

DOI: Digital Object Identifier

10.1177/1078155218783238

Related Literature

Article Analysis
・Side Effects of enalapril
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.